ERBB2 and neoplasm: Subsequent bi-variable analysis of patient sociodemographic and tumor clinicopathologic characteristics reveal that the following factors influence the likelihood of Anti-Her2 therapy administration: 1) CET administration, 86.9% of patients in the CET cohort received Anti-Her2 therapy as well while 13.1% did not (p<0.001).